Keyphrases
SARS-CoV-2 Variants
66%
Missouri
66%
Bourbon Virus
66%
Monoclonal Antibody
61%
Virus
55%
Variants of Concern
55%
COVID-19
55%
St. Louis
41%
Vaccine Response
33%
Conserved Epitopes
33%
Emerging Variants
33%
Variant Strain
33%
Environmental Field
33%
Public Antibody
33%
D614G
33%
Heartland Virus
33%
Antibody Efficacy
33%
Binding Residues
33%
Red Fox
33%
Bobcat
33%
Serosurveillance
33%
Coyote
33%
Virus-neutralizing Antibody
33%
Neutralizing Activity
27%
Neutralizing Antibodies
25%
SARS-CoV-2 Vaccination
22%
AbbVie
22%
LY-CoV555
22%
SARS-CoV-2 Infection
22%
Receptor-binding Domain
22%
Transmissibility
16%
Spike Protein
16%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
16%
Sampling Site
16%
Public Health Risk
16%
Clonal Analysis
11%
B Cells
11%
Neutralizing Capacity
11%
Angiotensin-converting Enzyme 2 (ACE2)
11%
Lung Viral Load
11%
AstraZeneca
11%
Clinical Development
11%
Immunodeficient Mice
11%
Antigenic Variant
11%
Cell Culture Experiment
11%
In Vivo Activity
11%
Public Clonotypes
11%
Protective Behavior
11%
SARS-CoV-2 mRNA Vaccine
11%
Partial Loss
11%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Human Immunodeficiency Virus 1
100%
Virus
96%
Viral Load
71%
Human Immunodeficiency Virus
66%
Lynx rufus
66%
Monoclonal Antibody
52%
Neutralizing Antibody
46%
Quantitative Reverse Transcription Polymerase Chain Reaction
41%
Spike
34%
Epitope
33%
Prevalence
33%
Human Immunodeficiency Virus 2
33%
Mutational Load
33%
Drug Resistance
33%
Coyote
33%
Vulpes vulpes
33%
RNA Virus
17%
Cell Culture
16%
Raccoon
14%
Receptor Binding
14%
Transgenic Mouse
13%
Amblyomma Americanum
10%
B Cell
9%
Angiotensin
9%
Drug Megadose
8%
SARS Coronavirus
8%
Hyalomma
7%
White Tailed Deer
7%
Seropositivity
7%
Didelphis virginiana
7%
Amplicon
6%
Nymph
5%